Target intelligence / Profile preview

Heat shock protein beta-11 (HSPB11) (HSPB11)

Target
HSPB11
Molecular classification
Other
01

Overview

Heat shock protein 16.2 (HSP16.2), widely recognized in human nomenclature as heat shock protein beta-11 (HSPB11), is a small heat shock protein (sHSP) that serves dual roles as a molecular chaperone and a component of the intraflagellar transport (IFT) machinery. In its chaperone capacity, it functions as an ATP-independent 'holdase' that sequesters misfolded proteins to prevent their aggregation during cellular stress. It also exerts significant anti-apoptotic effects by stabilizing mitochondrial membranes and inhibiting mitochondrial fission through the modulation of DLP1 phosphorylation. Clinically, HSP16.2 is a notable biomarker and potential therapeutic target in oncology; its elevated expression is strongly correlated with increased malignancy, poor response to radiochemotherapy, and survival in brain, esophageal, and hepatocellular cancers. In neurodegenerative research, it is investigated for its ability to mitigate proteotoxicity by interacting with amyloid-beta and alpha-synuclein aggregates. Additionally, HSP16.2 is a well-established biomarker for longevity and individual stress resistance in model organisms like C. elegans, where its induction levels early in life predict future lifespan.

Other names
Heat shock protein 16.2HSP16.2Intraflagellar transport protein 25 homologIFT25C1orf41PP25Small heat shock protein 16.2
02

Mechanism of action

Acts as an ATP-independent molecular chaperone (holdase) that prevents the irreversible aggregation of misfolded proteins and stabilizes mitochondrial membranes to inhibit apoptosis. It also functions as a component of the intraflagellar transport (IFT) complex B, facilitating ciliary transport and Hedgehog (Shh) signaling pathway modulation.

03

Biological functions

ApoptosisSignal transductionStress responseProtein foldingCell survivalOther
04

Disease associations

CancerNeurodegenerative diseaseOther
05

Safety considerations

Therapeutic resistance to chemotherapy (e.g., paclitaxel) due to overexpression in tumorsPotential for systemic proteotoxicity if chaperone function is inhibitedPossible disruption of ciliary-mediated signaling if transport functions are affected
06

Interacting drugs

Ginkgo biloba extract (EGb 761)

3 more in the full profile.

07

Biomarkers

HSP16.2 cytoplasmic expression levelsHSP16.2-GFP reporter (longevity/stress biomarker)HSPB11 mRNA levels in hepatocellular carcinoma

Beyond the preview

Go deeper on Heat shock protein beta-11 (HSPB11) (HSPB11).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heat shock protein beta-11 (HSPB11) (HSPB11).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call